SEC Form 4 · accession 0001019056-16-001461
Aptevo Therapeutics Inc. · APVO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
Jeffrey G. Lamothe
Officer — SVP, CFO and Treasurer
Period of report
Aug 3, 2016
Accepted (ET)
Aug 5, 2016 · 8:32 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001671584
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | holding | — | — | — | 1,047 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitF2,F3 | — | Aug 3, 2016 | A | 50,680 | A | — | — | Common Stock | 50,680 | 50,680 | D |
Explanation of responses
- F1Shares received in a pro rata distribution by Emergent BioSolutions Inc. ("Emergent") as a result of the spin-off of the Issuer from Emergent, effective on August 1, 2016.
- F2Each restricted stock unit represents the right of Mr. Lamothe to receive one share of common stock of the Issuer.
- F3The restricted stock units were granted on August 3, 2016 and will vest as follows: (i) 25,340 on January 31, 2017 and (ii) 25,340 on January 31, 2018.